Evidence map›Paper›PMID 39373572›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

In Vivo CRISPR Screening Reveals CHD7 as a Positive Regulator of Short-lived Effector Cells.

Martin W LaFleur, Jasmin M D'Andrea, Dillon G Patterson, Ivy S L Streeter, Matthew A Coxe, Jossef F Osborn, Lauren E Milling, Qin Tjokrosurjo, Jacob E Gillis, Thao H Nguyen and 4 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Martin W LaFleurDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-5017-774X
Jasmin M D'AndreaDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Dillon G PattersonDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Ivy S L StreeterDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.ORCID 0000-0003-0729-1042
Matthew A CoxeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-8791-7094
Jossef F OsbornDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-3867-8509
Lauren E MillingDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.ORCID 0009-0002-4604-9435
Qin TjokrosurjoDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Jacob E GillisDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Thao H NguyenDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Marc A SchwartzMassachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0003-3869-0150
Nir HacohenMassachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA.ORCID 0000-0002-3707-9889
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.

Funding

Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8M
Understanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca, DAVID A REARDON · 2020 to 2026
$19.5M
Project 2: Genes required for dendritic cell responses to pathogens and T cellsU19AI133524 · NIAID · HARVARD MEDICAL SCHOOL · PI SHARPE, ARLENE H. · 2017 to 2021
$12.3M
Cancer Research Institute (CRI) CRI4668HHS | NIH | National Cancer Institute (NCI) 5P50CA236749-03HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI133524NCI NIH HHS P01 CA236749NIAID NIH HHS P01 AI056299NIAID NIH HHS P01 AI108545NIAID NIH HHS U19 AI133524
6 · The paper itself

Abstract

CD8+ T cells differentiate into two subpopulations in response to acute viral infection: memory precursor effector cells (MPECs) and short-lived effector cells (SLECs). MPECs and SLECs are epigenetically distinct; however, the epigenetic regulators required for formation of these subpopulations are mostly unknown. In this study, we performed an in vivo CRISPR screen in murine naive CD8+ T cells to identify the epigenetic regulators required for MPEC and SLEC formation, using the acute lymphocytic choriomeningitis virus Armstrong infection model. We identified the ATP-dependent chromatin remodeler CHD7 (chromodomain-helicase DNA-binding protein 7) as a positive regulator of SLEC formation, as knockout (KO) of Chd7 reduced SLECs numerically. In contrast, KO of Chd7 increased the formation of central memory T cells following pathogen clearance yet attenuated memory cell expansion following a rechallenge. These findings establish CHD7 as a novel positive regulator of SLEC and a negative regulator of central memory T cell formation.

Indexed as

CD8-Positive T-LymphocytesDNA-Binding ProteinsLymphocytic choriomeningitis virusMice, KnockoutAnimalsCell DifferentiationClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsDNA HelicasesEpigenesis, GeneticImmunologic MemoryLymphocytic ChoriomeningitisMemory T CellsMiceMice, Inbred C57BLChd7 protein, mouseDNA-Binding ProteinsDNA Helicases

Identifiers

PMID39373572
PMCPMC11578095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.